The National Agency for Food and Drug Administration and Control (NAFDAC) hereby issues this public notice to inform all stakeholders, importers, distributors, healthcare practitioners, and the general public of the blacklisting of Anhui Hongye Pharmaceutical Co., Ltd, located at Fengyang East Road 76, Bengbu, Anhui Province, China.

Following a regulatory investigation, NAFDAC has confirmed that the company manufactured and supplied unregistered pharmaceutical products into the Nigerian market, including the following brands of Oxytocin injection:
A‑Tocin, Extocin, Gold Vision, and Claxitodin.

These actions constitute a serious violation of Nigerian drug regulatory laws and pose significant risks to public health.

Effective immediately, the following measures have been instituted:

1. Operational Blacklisting: Anhui Hongye Pharmaceutical Co., Ltd is placed on the NAFDAC operational blacklist. All current and future applications, registrations, and regulatory engagements with the company are suspended until further notice.
2. Product Withdrawal & Market Block: All products manufactured by Anhui Hongye Pharmaceutical Co., Ltd are to be withdrawn from Nigerian markets, entry points, and distribution channels. Importers and distributors are directed to immediately cease importation, sale, and distribution of these products. Enforcement action will be carried out nationwide.
3. Regulatory & Legal Sanctions: Any attempt to circumvent this directive—including rebranding, proxy importation, or indirect distribution—will result in product seizure, financial penalties, suspension of import licenses, and possible prosecution under Nigerian law.

Failure by the blacklisted company to comply with this suspension may result in further international regulatory escalation.

All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the substandard/falsified products within their zones and states.

NAFDAC urges distributors, suppliers, wholesalers, healthcare providers, and patients to exercise caution and vigilance along the supply chain to prevent the distribution, sale, administration, and use of unauthorized products. All medical products should only be obtained from legitimate sources. authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked. 

If you have any of the products mentioned above, please stop selling or using them immediately and submit your stock to the nearest NAFDAC office. If you or someone you know has used any of these products and experienced adverse reactions or events, we strongly recommend seeking immediate medical advice from a qualified healthcare professional.

Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng

Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the medicinal product to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med-safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng  

Thank you.

Prof. Mojisola Christianah Adeyeye FAS
Director General